AIMBE
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer. Rather than targeting cancer cells directly, the new strategy—which they suggest is akin to that of the Trojan horse—targets the tumor-associated macrophages (TAMs) that protect the tumor and keep the tumor microenvironment (TME) immunosuppressed.
The team developed IL-12-producing CAR T cells that directly target and disarm these tumor-associated macrophages, opening the tumor’s gates for the immune system to then enter and wipe out the cancer cells. The researchers demonstrated that the CAR T cell therapy increased survival in aggressive preclinical models of metastatic ovarian and lung cancer, and suggest that results could point to a new strategy for treating advanced-stage solid tumors… Continue reading.
